SYNB1353
- Generic Name
- SYNB1353
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Background
SYNB1353 is a strain of the probiotic bacteria Escherichia coli (E. coli) type Nissle and an engineered probiotic drug. Developed by Synlogic Operating Company, Inc., SYNB1353 is being investigated for the treatment of homocystinuria. It is designed to consume methionine in the gastrointestinal tract to prevent its absorption and conversion into homocysteine...
- Associated Conditions
- -
- Associated Therapies
- -
Safety, Tolerability and Pharmacodynamics of SYNB1353 in Healthy Adult Volunteers
- First Posted Date
- 2022-07-18
- Last Posted Date
- 2023-03-17
- Lead Sponsor
- Synlogic
- Target Recruit Count
- 31
- Registration Number
- NCT05462132
- Locations
- 🇺🇸
High Point Clinical Trials Center, High Point, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath